Table 3.
Comparison of patients with and without AKI
| Characteristics of Patients | AKI (n = 57) | non-AKI (n = 14) | P-value |
|---|---|---|---|
| Male, n (%) | 46 (81) | 9 (64) | 0.28 |
| Age (years), mean ± SD | 61.7 ± 11.4 | 59.1 ± 15.0 | 0.54 |
| BMI, mean ± SD | 31.7 ± 5.9 | 28.4 ± 4.9 | 0.04 |
| Basal SCr (µmol/L), mean ± SD | 70.4 ± 21.4 | 62.4 ± 17.6 | 0.16 |
| MAP (mmHg), mean ± SD | 92.8 ± 19.9 | 98.6 ± 11.6 | 0.17 |
| Maximal SCr (µmol/L), mean ± SD | 214.1 ± 183.0 | 76.8 ± 19.3 | <0.001 |
| Minimum diuresis (mL/kg/h), mean ± SD | 0.5 ± 0.3 | 0.6 ± 0.2 | 0.03 |
| PaO2/FiO2 at admission, median (IQR) | 150 (94–222) | 220 (172–249) | 0.07 |
| SAPSII, mean ± SD | 42.8 ± 16.5 | 34.4 ± 18.3 | 0.13 |
| SOFA score, mean ± SD | 7 ± 3.8 | 3.9 ±3.2 | 0.006 |
| Respiratory | 2.8 ± 0.9 | 2.3 ± 0.9 | 0.06 |
| Coagulation | 0.2 ± 0.5 | 0.2 ± 0.6 | 0.90 |
| Liver | 0.1 ± 0.5 | 0.1 ± 0.5 | 0.99 |
| Cardiovascular | 1.6 ± 1.5 | 0.4 ± 0.8 | 0.004 |
| Neurologic | 1.5 ± 1.8 | 0.8 ± 1.7 | 0.22 |
| Renal | 0.7 ± 1.1 | 0 ± 00 | <0.001 |
| Specific therapy, n (%) | |||
| Hydroxychloroquine | 31/57 (54) | 9/14 (64) | 0.56 |
| Lopinavir–Ritonavir | 21/57 (37) | 4/14 (29) | 0.76 |
| Tocilizumab | 5/57 (9) | 0/14 (0) | 0.57 |
| Crystalloid infusion during the first 24 h (mL), mean ± SD | 3074 ± 1577 | 2761 ± 905 | 0.37 |
| Contrast agent, n (%) | 12/57 (21) | 3/57 (21) | 0.98 |
| Worst PaO2/FiO2, median (IQR) | 93 (76–120) | 108 (90–227) | 0.04 |
| Maximal NE infusion (µg/kg/min), median (IQR) | 0.16 (0.10–0.39) | 0.23 (0.12–0.30) | 0.76 |
| Lactate level at maximal NE infusion (mmol/L), mean ± SD | 1.5 ± 0.7 | 1.5 ± 0.3 | 0.76 |
| C-reactive protein (mg/L) at admission, mean ± SD | 164 ± 111 | 125 ± 72 | 0.12 |
| Ferritin (ng/mL) at admission, mean ± SD | 1873 ± 1778 | 2103 ± 1686 | 0.68 |
| Lymphocytes at admission (/mm3), mean ± SD | 939 ± 590 | 782 ± 342 | 0.20 |
| AKI Stage 1, n (%) | 20/57 (35) | ||
| AKI Stage 2, n (%) | 20/57 (35) | ||
| AKI Stage 3, n (%) | 17/57 (30) | ||
| AKD Stage 1, n (%) | 2/57 (4) | ||
| AKD Stage 2, n (%) | 7/57 (12) | ||
| AKD Stage 3, n (%) | 9/57 (16) | ||
| Total AKD | 18/57 (32) | ||
| MAKEs, n (%) | 19 (33) | 0 | |
| SCr >200 µmol/L | 9/19 (47) | ||
| Dialysis at Day 7 | 6/19 (32) | ||
| Death | 4/19 (21) | ||
BMI, body mass index; FiO2, fraction of inspired oxygen; MAP, mean arterial pressure; NE, norepinephrine; PaO2, arterial partial pressure of oxygen; SAPS, simplified acute physiology score.